8-K: Allogene Therapeutics Reports Q1 2025 Financial Results and Provides Business Update

Allogene Therapeutics announces its Q1 2025 financial results, highlighting progress in its ALPHA3 trial for LBCL and the RESOLUTION trial for autoimmune diseases, while extending its cash runway into the second half of 2027 through cost realignment.

Summary

• Allogene Therapeutics reported its Q1 2025 financial results and provided a business update on May 13, 2025.
• The company is focusing on advancing its Cema-Cel/ALPHA3 trial for Large B-Cell Lymphoma (LBCL) and ALLO-329/RESOLUTION clinical trials for autoimmune diseases.
• The pivotal Phase 2 ALPHA3 trial has nearly 50 activated sites across the U.S.
• Over 250 patients have consented for MRD screening in the ALPHA3 trial, with nearly half in the last three months.
• International expansion of the ALPHA3 trial will begin in Canada in Q2 2025.
• The Phase 1 RESOLUTION trial with ALLO-329 in autoimmune disease is on track for a mid-2025 start.
• Updated Phase 1 trial results for ALLO-316 in Renal Cell Carcinoma (RCC) will be presented at the 2025 ASCO Annual Meeting.
• Allogene ended Q1 2025 with $335.5 million in cash, cash equivalents, and investments.
• Cost realignment and strategic prioritization will extend the cash runway into 2H 2027.
• New guidance for 2025 is an expected decrease in cash, cash equivalents, and investments of approximately $150 million.
• GAAP Operating Expenses are now expected to be approximately $230 million, including estimated non-cash stock-based compensation expense of approximately $45 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there are some delays in trial milestones, the company is making progress in its clinical programs, has a solid cash position, and has extended its cash runway through cost realignment. Management's comments are optimistic about the company's future.

Positives

• The ALPHA3 trial is progressing with nearly 50 activated sites and strong investigator enthusiasm.
• Patient consent for MRD screening in the ALPHA3 trial is increasing, indicating growing momentum.
• International expansion of the ALPHA3 trial is planned for Q2 2025, which could accelerate enrollment.
• The RESOLUTION trial for autoimmune disease is on track for a mid-2025 start.
• Updated data from the ALLO-316 trial in RCC will be presented at ASCO 2025.
• The company has a solid cash position of $335.5 million as of March 31, 2025.
• Cost realignment efforts have extended the cash runway into the second half of 2027.

Negatives

• The milestone for lymphodepletion regimen selection and futility analysis in the ALPHA3 trial has been delayed to the first half of 2026 due to site-related factors.
• The first update to the ALLO-329 program has been shifted to 1H 2026 to allow for both biomarker and clinical proof-of-concept data.

Risks

• The success of the ALPHA3 trial is crucial for the regulatory approval of cema-cel.
• Delays in site readiness have impacted the pace of screening in the ALPHA3 trial.
• The development of AlloCAR T products is based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and obtaining regulatory approval.
• The company may encounter difficulties enrolling patients in its clinical trials.
• The company may not be able to demonstrate the safety and efficacy of its product candidates in its clinical trials, which could prevent or delay regulatory approval and commercialization.
• There are challenges with manufacturing or optimizing manufacturing of the company's product candidates.

Future Outlook

Allogene expects its cost realignment and strategic prioritization to extend its cash runway into the second half of 2027 and anticipates a decrease in cash, cash equivalents, and investments of approximately $150 million for 2025, with GAAP operating expenses around $230 million.

Management Comments

• We are executing on a strategy that is grounded in science, shaped by real-world insights, and supported by a platform purpose-built to scale, said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene.
• From transforming the role of CAR T in first-line LBCL through ALPHA3 to breaking new ground in autoimmune disease with ALLO-329 to showing whats possible in solid tumors with ALLO-316, we are leading where others have yet to go.
• The experience weve gained from our trials, the commitment from our partners, and the unmatched efficiencies of our allogeneic platform reinforce my confidence that our approach is not only working but also defining the future of cell therapy.
• We have never been clearer about our path or more certain about the value we can deliver to patients and the field.

Industry Context

Allogene is positioning itself as a leader in the allogeneic CAR T therapy space, targeting both cancer and autoimmune diseases. The company's focus on off-the-shelf CAR T products aims to address the limitations of autologous CAR T therapies, such as manufacturing complexities and patient-specific requirements. The expansion into autoimmune diseases with ALLO-329 represents a novel approach in the field.

Comparison to Industry Standards

• Allogene's ALPHA3 trial is unique in its approach to using MRD testing to identify high-risk LBCL patients for consolidation therapy, a strategy not commonly employed in standard of care.
• The company's ALLO-329 program targeting both CD19 and CD70 in autoimmune diseases is a novel approach compared to other CAR T therapies that typically target a single antigen.
• Allogene's cash runway extension into 2H 2027 provides a competitive advantage compared to other biotech companies facing financial constraints in the current macroeconomic environment.
• Companies like Gilead (Kite Pharma) and Novartis are major players in the autologous CAR-T space, while Allogene is focused on allogeneic CAR-T therapies, which could offer advantages in terms of scalability and accessibility.
• Allogene's approach to solid tumors with ALLO-316 is notable, as solid tumors have been a challenging area for CAR T therapy development.

Stakeholder Impact

• Shareholders: The extended cash runway and focus on key clinical programs are positive for shareholder value.
• Patients: Progress in clinical trials offers potential new treatment options for cancer and autoimmune diseases.
• Employees: Cost realignment may impact some employees, but the company is preserving core capabilities.
• Clinical Sites: Strong partnerships with clinical sites are crucial for the success of the ALPHA3 trial.

Next Steps

• Continue enrollment and site activation for the ALPHA3 trial.
• Initiate international expansion of the ALPHA3 trial in Canada in Q2 2025.
• Start the Phase 1 RESOLUTION trial in rheumatology in mid-2025.
• Present updated Phase 1 trial results for ALLO-316 at the ASCO Annual Meeting on June 1, 2025.
• Achieve the milestone for lymphodepletion regimen selection and futility analysis in the ALPHA3 trial in the first half of 2026.
• Provide the first update to the ALLO-329 program with biomarker and clinical proof-of-concept data in 1H 2026.

Key Dates

Keywords

Allogene Therapeutics, AlloCAR T, Cema-Cel, ALPHA3 Trial, ALLO-329, RESOLUTION Trial, ALLO-316, Renal Cell Carcinoma, Autoimmune Disease, LBCL, Clinical Trials, Financial Results